Metformin – the old drug with new therapeutic possibilities DOI Open Access
Paulina Oleksa, Kacper Jasiński, Daria Żuraw

et al.

Polish Journal of Public Health, Journal Year: 2024, Volume and Issue: 134, P. 47 - 51

Published: Sept. 20, 2024

Original Article, Pol J Public Health, Vol. 134 (2024): 47-51 Paulina Oleksa, Kacper Jasiński, Daria Żuraw, Mateusz Sobczyk, Monika Żybowska, Anna Rzewuska-Fijałkowska, Karolina Haczkur-Pawłowska, Piotr Więsyk Students’ Scientific Society at the Department of Epidemiology and Clinical Research Methodology, Medical University Lublin, Poland Introduction. Metformin is an oral antidiabetic drug from biguanide group, popularly referred as aspirin 21st century. The therapeutic targets metformin are expanding. It characterized by antineoplastic, immunoregulatory, anti-aging neuroprotective properties. We aimed to evaluate pleiotropic effects metformin, taking into account its different mechanisms, efficacy safety in contemporary public health challenges. Material methods. conducted literature review 2014 2024 using PubMed Google Scholar. Results. Metformin, depending on cancer stage, enhances treatment effects, prevents resistance, lengthens overall time survival, reduces risk recurrence. In Parkinson’s disease, Alzheimer’s disease depression can even increase their occurrence, especially high doses. Such doses predispose cobalamin deficiency, affecting functioning nervous system. was effective seizure control epilepsy. has positive impact course some autoimmunological diseases. Among diabetics treatment, outcomes COVID-19 tuberculosis could be improved metformin. Conclusions. pluripotential drug. Possibilities adjuvant therapy very promising, but it cannot recommended standard treatment. This issue requires further investigation, preferentially randomized controlled trials bigger research samples. Keywords: therapy, advances.

Language: Английский

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study DOI
Huilin Tang, Ying Lü, Michael S. Okun

et al.

Movement Disorders, Journal Year: 2024, Volume and Issue: 39(11), P. 1960 - 1970

Published: Aug. 27, 2024

Abstract Background Previous studies have suggested that glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) may a disease‐modifying effect in the development of Parkinson's disease (PD), but population yielded inconsistent results. Objective The aim was to compare risk PD associated with GLP‐1RAs compared dipeptidyl peptidase 4 inhibitors (DPP4i) among older adults type 2 diabetes (T2D). Methods Using U.S. Medicare administrative data from 2016 2020, we conducted population‐based cohort study comparing new use GLP‐1RA DPP4i aged ≥66 years T2D. primary endpoint diagnosis PD. A stabilized inverse probability treatment weighting (sIPTW)–adjusted Cox proportional hazards regression model employed estimate hazard ratio (HR) and 95% confidence intervals (CI) for between users. Results This included 89,074 beneficiaries who initiated either (n = 30,091) or 58,983). crude incidence rate lower users than (2.85 vs. 3.92 patients per 1000 person‐years). An sIPTW‐adjusted showed were 23% (HR, 0.77; CI, 0.63–0.95). Our findings largely consistent across different subgroup analyses such as sex, race, molecular structure GLP‐1RA. Conclusion Among T2D, significantly decreased DPP4i. © 2024 International Parkinson Movement Disorder Society.

Language: Английский

Citations

5
Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment DOI Open Access
C. Duta,

Corina Muscurel,

Carmen Beatrice Dogaru

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1516 - 1516

Published: Feb. 11, 2025

This review explores the promising potential of repurposing type 2 diabetes (T2D) medications for treatment Parkinson's disease (PD), highlighting shared pathophysiological mechanisms between these two age-related conditions, such as oxidative stress, mitochondrial dysfunction, and ferroptosis. The overlap suggests that existing drugs could target common pathways involved in both conditions. Specifically, discusses how T2D medications, including metformin (Met), peroxisome-proliferator-activated receptor gamma (PPAR-γ) agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, incretins, dipeptidyl-peptidase 4 (DPP-4) can improve function, reduce neuroinflammation potentially inhibit connection ferroptosis treatments, medication, are only beginning to be explored. limited data attributed also complexity fact specific role pathogenesis has not been a primary focus until recent. Despite preclinical evidence, clinical findings mixed, underscoring need further research elucidate drugs' roles neurodegeneration. Repurposing have well-established safety profiles significantly time cost associated with drug development offer more comprehensive approach managing compared treatments targeting single mechanism.

Language: Английский

Citations

0
Modifiable risk factors associated with the risk of developing Parkinson's disease: a critical review DOI Creative Commons
Vítor Tumas,

Marcelo Jhonatan Aureliano,

Carlos Roberto de Mello Rieder

et al.

Arquivos de Neuro-Psiquiatria, Journal Year: 2025, Volume and Issue: 83(03), P. 001 - 010

Published: March 1, 2025

The etiology of Parkinson's disease (PD) is complex and multifactorial, depending on interactions involving environmental/lifestyle genetic factors. aspects the are becoming well characterized, while environmental factors still need further investigation. In present narrative review, we have described most concrete evidence associations between risk developing PD. Physical activity, healthy dietary patterns, smoking, caffeine intake protective against Head trauma, consumption milk dairy products, pesticide exposure were associated with a higher alcohol consumption, living in rural areas, farming, water PD controversial. Results several studies strongly suggest that diabetes mellitus factor for development PD, as pre-diabetic state. Lower serum levels uric acid an increased worse clinical features faster progression symptoms. effects nonsteroidal antiinflammatory drugs use Several other potentially PD: pollutants such organic solvents, to sunlight, vitamin D deficiency, bullous pemphigoid, bipolar disorder, inflammatory bowel disease, irritable syndrome, certain infections agents, essential tremor. Environmental important markers Understanding these risks could lead implementation risk-modifying actions

Language: Английский

Citations

0
Metformin: The Winding Path from Understanding Its Molecular Mechanisms to Proving Therapeutic Benefits in Neurodegenerative Disorders DOI Creative Commons
Laura Mihaela Isop, Andrea Elena Neculau, Radu Necula

et al.

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(12), P. 1714 - 1714

Published: Dec. 11, 2023

Metformin, a widely prescribed medication for type 2 diabetes, has garnered increasing attention its potential neuroprotective properties due to the growing demand treatments Alzheimer's, Parkinson's, and motor neuron diseases. This review synthesizes experimental clinical studies on metformin's mechanisms of action therapeutic benefits neurodegenerative disorders. A comprehensive search electronic databases, including PubMed, MEDLINE, Embase, Cochrane library, focused key phrases such as "metformin", "neuroprotection", "neurodegenerative diseases", with data up September 2023. Recent research glucoregulatory reveals new molecular targets, activation LKB1-AMPK signaling pathway, which is crucial chronic administration metformin. The pleiotropic impact may involve other stress kinases that are acutely activated. precise role respiratory chain complexes (I IV), mitochondrial or lysosomes in metformin effects remains be established by further research. Research extrahepatic targets like gut microbiota, well antioxidant immunomodulatory properties, understanding Experimental animal models shows promising results, but inconclusive. Understanding could help design trials explore and, hopefully, prove conditions.

Language: Английский

Citations

10
Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases? DOI Open Access
Nadia Papini, Paola Giussani, Cristina Tringali

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 8884 - 8884

Published: Aug. 15, 2024

Metformin is a widely employed drug in type 2 diabetes. In addition to warranting good short- and long-term glycemic control, metformin displays many intriguing properties as protection against cardiovascular neurodegenerative diseases, anti-tumorigenic longevity promotion. being low-cost drug, generally well tolerated. However, despite the enthusiastic drive aliment these novel studies, contradictory results suggest importance of better elucidating complexity action different tissues/cells establish its possible employment diseases. This review summarises recent data identifying lysosomal-dependent processes lysosomal targets, such endosomal Na+/H+ exchangers, presenilin enhancer (PEN2), pathway leading AMP-activated protein kinase (AMPK) activation, transcription factor EB (TFEB), modulated by metformin. Lysosomal dysfunctions resulting autophagic acidification biogenesis impairment appear be hallmarks inherited acquired Lysosomes are not yet seen sort cellular dump but crucial determining key signalling paths involved clearance aggregated proteins. Thus, possibility pharmacologically modulating them deserves great interest. Despite potentiality this context, additional important issues, dosing, should addressed future.

Language: Английский

Citations

2
Frailty and Parkinson’s disease: the role of diabetes mellitus DOI Creative Commons
Klara Komici,

Antonella Pansini,

Leonardo Bencivenga

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: May 30, 2024

Parkinson’s disease (PD) is a chronic neurodegenerative associated with progressive loss of dopaminergic neurons, clinically characterized by motor and non-motor signs. Frailty clinical condition increased vulnerability negative health outcomes due to the multiple physiological reserves. Chronic hyperglycemia insulin resistance, which characterize diabetes mellitus (DM), have been reported alter activity, increase risk PD, influence development frailty. Even though may facilitate frailty in patients this relationship not established revision current knowledge necessary. Furthermore, synergy between DM, drive complexity, worse outcomes, under-representation these populations research. In review, we aimed discuss role among PD. We summarized characteristics concomitant Finally, interventions prevent population are discussed.

Language: Английский

Citations

2
Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study DOI

Yingjie Zhao,

Fei Lu,

Yongtao Duan

et al.

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Journal Year: 2024, Volume and Issue: 135, P. 111128 - 111128

Published: Aug. 23, 2024

Language: Английский

Citations

2
To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists DOI

Lindsay R. Hunter Guevara,

William B. Beam,

Jeffrey J. Pasternak

et al.

Journal of Neurosurgical Anesthesiology, Journal Year: 2024, Volume and Issue: 36(4), P. 278 - 282

Published: July 31, 2024

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as an increasingly popular class of medications commonly used for glycemic control in patients with type 2 diabetes mellitus and weight loss. GLP-1 RAs also potential benefits various neurological diseases independent their glucose-modulating effect. In this focused review, we explore animal clinical evidence evaluating the impact common diseases. Our aim is to provide a basis hypothesis generation future studies assess role that may on nervous system, including implications perioperative period.

Language: Английский

Citations

1
Metformin – the old drug with new therapeutic possibilities DOI Open Access
Paulina Oleksa, Kacper Jasiński, Daria Żuraw

et al.

Polish Journal of Public Health, Journal Year: 2024, Volume and Issue: 134, P. 47 - 51

Published: Sept. 20, 2024

Original Article, Pol J Public Health, Vol. 134 (2024): 47-51 Paulina Oleksa, Kacper Jasiński, Daria Żuraw, Mateusz Sobczyk, Monika Żybowska, Anna Rzewuska-Fijałkowska, Karolina Haczkur-Pawłowska, Piotr Więsyk Students’ Scientific Society at the Department of Epidemiology and Clinical Research Methodology, Medical University Lublin, Poland Introduction. Metformin is an oral antidiabetic drug from biguanide group, popularly referred as aspirin 21st century. The therapeutic targets metformin are expanding. It characterized by antineoplastic, immunoregulatory, anti-aging neuroprotective properties. We aimed to evaluate pleiotropic effects metformin, taking into account its different mechanisms, efficacy safety in contemporary public health challenges. Material methods. conducted literature review 2014 2024 using PubMed Google Scholar. Results. Metformin, depending on cancer stage, enhances treatment effects, prevents resistance, lengthens overall time survival, reduces risk recurrence. In Parkinson’s disease, Alzheimer’s disease depression can even increase their occurrence, especially high doses. Such doses predispose cobalamin deficiency, affecting functioning nervous system. was effective seizure control epilepsy. has positive impact course some autoimmunological diseases. Among diabetics treatment, outcomes COVID-19 tuberculosis could be improved metformin. Conclusions. pluripotential drug. Possibilities adjuvant therapy very promising, but it cannot recommended standard treatment. This issue requires further investigation, preferentially randomized controlled trials bigger research samples. Keywords: therapy, advances.

Language: Английский

Citations

0